INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Price & Overview

NASDAQ:NVIV • US46186M6057

0.3207 USD
-0.17 (-34.28%)
At close: Feb 12, 2024
0.231 USD
-0.09 (-27.97%)
After Hours: 2/12/2024, 8:01:31 PM

The current stock price of NVIV is 0.3207 USD. Today NVIV is down by -34.28%. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.

NVIV Key Statistics

52-Week Range0.222 - 2.16
Current NVIV stock price positioned within its 52-week range.
1-Month Range0.222 - 1.05
Current NVIV stock price positioned within its 1-month range.
Market Cap
997.377K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.52
Dividend Yield
N/A

NVIV Stock Performance

Today
-34.28%
1 Week
+44.46%
1 Month
-58.69%
3 Months
-53.52%
Longer-term
6 Months -71.62%
1 Year -84.43%
2 Years -95.80%
3 Years -98.88%
5 Years -99.97%
10 Years N/A

NVIV Stock Chart

INVIVO THERAPEUTICS HOLDINGS / NVIV Daily stock chart

NVIV Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NVIV. When comparing the yearly performance of all stocks, NVIV is a bad performer in the overall market: 98.27% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
NVIV Full Technical Analysis Report

NVIV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NVIV. No worries on liquidiy or solvency for NVIV as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVIV Full Fundamental Analysis Report

NVIV Earnings

Next Earnings DateN/A
Last Earnings DateAug 9, 2023
PeriodQ3 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
NVIV Earnings History

NVIV Forecast & Estimates


Analysts
Analysts85.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
NVIV Forecast & Estimates

NVIV Groups

Sector & Classification

Index Membership

NVIV Financial Highlights

Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-9.33M
Industry RankSector Rank
PM (TTM) N/A
ROA -97.39%
ROE -104.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.06%
Sales Q2Q%N/A
EPS 1Y (TTM)56.05%
Revenue 1Y (TTM)N/A
NVIV financials

NVIV Ownership

Ownership
Inst Owners0.76%
Shares3.11M
Float2.77M
Ins Owners557.87%
Short Float %N/A
Short RatioN/A
NVIV Ownership

NVIV Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.19191.579B
ISRG INTUITIVE SURGICAL INC48.22175.033B
SYK STRYKER CORP22.86132.327B
BSX BOSTON SCIENTIFIC CORP19.91103.323B
EW EDWARDS LIFESCIENCES CORP28.6249.378B
IDXX IDEXX LABORATORIES INC40.5147.813B
BDX BECTON DICKINSON AND CO11.9746.461B
RMD RESMED INC19.5634.985B
GEHC GE HEALTHCARE TECHNOLOGY14.0633.11B
DXCM DEXCOM INC26.0825.52B
ZBH ZIMMER BIOMET HOLDINGS INC11.0518.338B
HOLX HOLOGIC INC15.3616.834B
PODD INSULET CORP36.9416.813B

About NVIV

Company Profile

NVIV logo image Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.

Company Info

IPO: 2006-11-14

INVIVO THERAPEUTICS HOLDINGS

Building 1400 East 4Th Floor, One Kendall Square

Cambridge MASSACHUSETTS 02139 US

CEO: Richard Toselli

Employees: 6

NVIV Company Website

Phone: 16178635524

INVIVO THERAPEUTICS HOLDINGS / NVIV FAQ

What does NVIV do?

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.


What is the current price of NVIV stock?

The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.


Does NVIV stock pay dividends?

NVIV does not pay a dividend.


How is the ChartMill rating for INVIVO THERAPEUTICS HOLDINGS?

NVIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of INVIVO THERAPEUTICS HOLDINGS (NVIV)?

INVIVO THERAPEUTICS HOLDINGS (NVIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).


Can you provide the market cap for INVIVO THERAPEUTICS HOLDINGS?

INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.